Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for DexCom in a research report issued ...

DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market capitalization of $34.8 billion, finds itself at a critical juncture as it ...

DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by ...

Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

Kingsview Wealth Management LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 45.0% in the 4th quarter, according to the company in its most recent disclosure with the ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.